These findings highlight the multifaceted role of inflammasomes in hypertension pathogenesis and suggest that targeting inflammasome pathways, beyond just NLRP3, may offer novel therapeutic strategies for hypertension management. This evidence concerns the gene NLRP3 and hypertensive disorder.